 |
인쇄하기
취소
|
Abbott to launch RS Virus antibody.
Abbott Korea announced to launch Synagis (palivizumab), a monoclonal antibody for the prevention of serious respiratory infection due to respiratory syncytial virus (RSV) infection in pediatric patients at high risk of RSV from Jan. 11 this year.
About 90% of hospitalized babies on a capillary bronchitis or 50% of babies on a winter seasonal pneumonia were found RSV infection, which is very ...
About 90% of hospitalized babies on a capillary bronchitis or 50% of babies on a winter seasonal pneumonia were found RSV infection, which is very ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.